

HIV Capsid Inhibitors: Mechanism of Action


David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington

July 9, 2024


Disclosures

Dr. Spach does not have any disclosures.

HIV Antiretroviral Therapy




HIV Antiretroviral Therapy: Capsid Inhibitors




Host cell

HIV Capsid Structure and Function


HIV



HIV Core




HIV Core and HIV Capsid




HIV Core and HIV Capsid


HIV Core




HIV Capsid




HIV Capsid Shell and Capsid Proteins



HIV Capsid Hexamers and Pentamers and HIV Capsid Shell




Capsid Hexamer




Capsid Pentamer




Function of HIV Core and HIV Capsid




Function of HIV Core and HIV Capsid




HIV Core Transport Inside Host Cell



HIV Core Transport Inside Host Cell




HIV Reverse Transcription




Lenacapavir and Capsid Binding

HIV Capsid Hexamer




Top view

↷ 90°



Side view

Lenacapavir Capsid Binding Pocket



Lenacapavir Binding to Capsid Hexamer

Lenacapavir

Top view




↗ 90°


Side view



Lenacapavir and Intra-Hexamer Binding



Top view




Side view

Lenacapavir Capsid Protein Binding Pocket

Lenacapavir




Lenacapavir and Inter-Hexamer Binding




Mechanism of Action of HIV Capsid Inhibitors


Capsid Inhibitors: Inhibition of Nuclear Import




Nuclear Import and Host Proteins




Nup 153 and Capsid Binding




CPSF6 and Capsid Binding




CPSF6 Augmented Capsid Migration to Host DNA SPAD Region




Lenacapavir Inhibition of Nup 153 and CPSF6 Capsid Binding




Lenacapavir and Inhibition of Nuclear Pore Transport




Lenacapavir and Inhibition of Capsid Migration to Host DNA



Capsid Inhibitors: Inhibition of Capsid Uncoating




Capsid Uncoating



Lenacapavir and Inhibition of Capsid Uncoating


Lenacapavir Stabilized Capsid



Cytoplasm


Lenacapavir and Inhibition of Capsid Uncoating

Lenacapavir Stabilized Capsid



Premature Capsid Disassembly


Lenacapavir Stabilized Capsid




Lenacapavir

Premature Capsid Rupture


Failure to Convert HIV RNA to HIV DNA



Capsid Inhibitors: Inhibition of Capsid Assembly




HIV Maturation




Host cell


HIV Capsid (Core) Formation




HIV Capsid (Core) Formation



HIV Polyproteins




Polyprotein Cleavage



HIV Capsid Formation


Monomers

Polymers




HIV Capsid Formation

Monomers Polymers Clusters




HIV Capsid Formation

Monomers Polymers Clusters Early Capsid Assembly



HIV Capsid Formation



Lenacapavir Bound to Capsid (p24) Hexamer

Lenacapavir

Top view




↷ 90°


Side view



Lenacapavir within p24 hexamer




Top view




Side view

HIV Capsid Assembly: Impact of Lenacapavir

HIV capsid assembly



Lenacapavir-bound capsid assembly



Fast


TIME




Slow

HIV Capsid Assembly: Impact of Lenacapavir

HIV capsid assembly



Lenacapavir-bound capsid assembly



TIME




Fast



Slow

HIV Capsid Assembly: Impact of Lenacapavir



Lenacapavir

Lenacapavir (*Sunlenca*)

Oral Lenacapavir



300 mg tablets

Take with or without food

Subcutaneous Lenacapavir



1.5 mL vial = 463.5 mg


Administer as Subcutaneous Injection

Lenacapavir (*Sunlenca*)



Dosing (Subcutaneous Injection)

- 2 x 1.5 mL single dose vials
- Inject 2 x 1.5 mL (927 mg total) every 6 months (26 weeks +/- 2 weeks)



Lenacapavir Dosing for HIV Treatment: Initiation Option 1

Initiation Option 1

Day 1



600 mg

Day 2



600 mg



927 mg



Oral lenacapavir 300 mg



Subcutaneous lenacapavir 463.5 mg

Lenacapavir Dosing for HIV Treatment: Initiation Option 1

Initiation Option 1

Day 1




Day 2



600 mg

600 mg

Month 6



6 months

927 mg



6 months

927 mg

Maintenance

Month 12



6 months

927 mg

Month 18



927 mg



Oral lenacapavir 300 mg



Subcutaneous lenacapavir 463.5 mg

Lenacapavir Dosing for HIV Treatment: Initiation Option 2

Initiation Option 2

Day 1 Day 2




600 mg 600 mg

Day 8



300 mg

Day 15



927 mg




Oral lenacapavir 300 mg



Subcutaneous lenacapavir 463.5 mg

Lenacapavir Dosing for HIV Treatment: Initiation Option 2



Lenacapavir Dosing for HIV PrEP

Initiation

Day 1




Day 2




600 mg

600 mg



927 mg

Month 6



927 mg

Maintenance

Month 12



927 mg

Month 18



927 mg

6 months

6 months

6 months



Oral lenacapavir 300 mg



Subcutaneous lenacapavir 463.5 mg

Summary

Capsid Inhibitors and Multistage Mechanism of Action

1

Inhibits Capsid Nuclear Import

2

Inhibits Capsid Uncoating

3

Inhibits Capsid Assembly

Acknowledgment

The production of this **National HIV Curriculum** Mini-Lecture was supported by Grant U1OHA32104 from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS). Its contents are solely the responsibility of University of Washington IDEA Program and do not necessarily represent the official views of HRSA or HHS.

